- Home
- Publications
- Publication Search
- Publication Details
Title
Refining sorafenib therapy: lessons from clinical practice
Authors
Keywords
-
Journal
Future Oncology
Volume 11, Issue 3, Pages 449-465
Publisher
Future Medicine Ltd
Online
2014-10-31
DOI
10.2217/fon.14.261
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- (2017) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival
- (2016) Alexandra Shingina et al. CANADIAN JOURNAL OF GASTROENTEROLOGY
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Sorafenib use in hepatocellular carcinoma: More questions than answers
- (2014) Ghassan K. Abou-Alfa HEPATOLOGY
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma
- (2013) N. Shinohara et al. ANNALS OF ONCOLOGY
- Sorafenib: from literature to clinical practice
- (2013) V. Di Marco et al. ANNALS OF ONCOLOGY
- Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma
- (2013) Luigi Bolondi et al. DIGESTIVE AND LIVER DISEASE
- Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma
- (2013) Massimo Colombo et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2013) Takahide Nakazawa et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?
- (2013) Giuseppe Cabibbo et al. Expert Review of Anticancer Therapy
- Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit
- (2013) Salvatore D’Angelo et al. Future Oncology
- Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma
- (2013) Calogero Cammà et al. HEPATOLOGY
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma
- (2013) Koji Miyahara et al. HEPATOLOGY RESEARCH
- GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
- (2013) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma
- (2013) Giovan Giuseppe Di Costanzo et al. MEDICAL ONCOLOGY
- A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- (2013) L. Rimassa et al. ONCOLOGIST
- Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series
- (2013) Liliana Montella et al. ONCOLOGY
- Recent Advancements in Comprehensive Genetic Analyses for Human Hepatocellular Carcinoma
- (2013) Naoshi Nishida et al. ONCOLOGY
- Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations
- (2013) A. Ruth He et al. Therapeutic Advances in Gastroenterology
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2012) Bassam Estfan et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- (2012) T. Pressiani et al. ANNALS OF ONCOLOGY
- Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) C. Verslype et al. ANNALS OF ONCOLOGY
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice
- (2012) Giovan Giuseppe Di Costanzo et al. DIGESTIVE AND LIVER DISEASE
- Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience
- (2012) Giuseppa Scandurra et al. Future Oncology
- Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib
- (2012) Carlo Spirli et al. HEPATOLOGY
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
- (2012) T. Eisen et al. JNCI-Journal of the National Cancer Institute
- Evaluation of the mRECIST and a-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib
- (2012) Tomokazu Kawaoka et al. ONCOLOGY
- Treatment of Hepatocellular Carcinoma with Sorafenib - Focus on Special Populations and Adverse Event Management
- (2012) E. Schott et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Cancer-related fatigue: a practical review
- (2011) M. P. O. Campos et al. ANNALS OF ONCOLOGY
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
- (2011) Julien Edeline et al. CANCER
- Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group
- (2011) Sergio Bracarda et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group
- (2011) Kim Edmonds et al. European Journal of Oncology Nursing
- Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib
- (2011) Giuseppe Cabibbo et al. Expert Review of Anticancer Therapy
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- The Outcomes and Safety of Single-Agent Sorafenib in the Treatment of Elderly Patients with Advanced Hepatocellular Carcinoma (HCC)
- (2011) H. Wong et al. ONCOLOGIST
- Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
- (2011) Teiji Kuzuya et al. ONCOLOGY
- Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib
- (2011) Giovanni Abbadessa WORLD JOURNAL OF GASTROENTEROLOGY
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- Experience with sorafenib and adverse event management
- (2010) Joaquim Bellmunt et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma
- (2010) Markus Peck-Radosavljevic et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study
- (2010) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2010) B. Vincenzi et al. ONCOLOGIST
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma
- (2009) Giuseppe Cabibbo et al. HEPATOLOGY
- Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
- (2009) Antonius A. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started